Результаты поиска

Case Report: Staged multidisciplinary nursing management of grade 4 oral mucositis after pediatric hematopoietic stem cell transplantation.

Severe oral mucositis (OM) after pediatric hematopoietic stem cell transplantation (HSCT) becomes especially challenging when complicated by pancytopenia, platelet transfusion refractoriness, bleeding, and high nutritional risk, which also make oral care hard to deliver. We report a 13-year-old girl with transfusion-dependent α-thalassemia who developed OM on day +6 after unrelated-donor HSCT and progressed to World Health Organization grade 4 on day +17, with severe ulceration, pseudomembrane, trismus, inability to eat, bleeding, and anxiety. The case focuses on how a staged, multidisciplinar…

Neurological graft-versus-host disease with MOG antibody positivity after allogeneic stem cell transplantation: a case report.

BACKGROUND: Central nervous system (CNS) involvement is recognized as a distinct manifestation of chronic GVHD (cGVHD). Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an autoimmune disorder targeting the CNS. Therefore, the occasional detection of MOG antibodies in patients with CNS-cGVHD may represent a manifestation within the spectrum of CNS-GVHD. CASE PRESENTATION: A 22-year-old female with severe aplastic anemia (AA) underwent maternal haploidentical hematopoietic stem cell transplantation (HSCT) in May 2021. During conditioning, she developed acute neurotoxic…

Real-World Effectiveness and Renal Safety of Foscarnet for CMV Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation.

Background/Objectives: Cytomegalovirus (CMV) reactivation is a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. Letermovir is used to prevent infections, but it is not available in many countries. Ganciclovir and valganciclovir carry a risk of bone marrow suppression. Foscarnet is frequently used as a bone marrow-sparing alternative; however, its clinical utility is constrained by nephrotoxicity. In this study, we aimed to evaluate the efficacy and renal safety of foscarnet and to identify factors associated with acute kidney injury

Совпадение в полном тексте источника
… Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation Haematologica 2006 91 78 83 16434374 4. Foster G.G. Grant M.J. Thomas S.M. Cameron B. Raiff D. Corbet K. Loitsch G. Ferreri C. Horwitz M. … Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant Kidney Int. 2005 67 1999 2005 10.1111/j.1523-1755.2005.00301.x 15840050 …

Late Endocrine and Organ Toxicities After Treosulfan-Based Conditioning in Pediatric Hematopoietic Cell Transplantation: A Systematic Review.

Treosulfan is an alkylating agent indicated as a conditioning agent for allogeneic hematopoietic cell transplantation (HCT), with an established favorable acute toxicity profile; however, its long-term sequelae remain incompletely characterized. This review aims to characterize the late effects following treosulfan-based conditioning in pediatric HCT and to identify critical gaps in published evidence. This systematic review was conducted in accordance with PRISMA guidelines and prospectively registered with PROSPERO (CRD420261345072). PubMed, Embase, and the Cochrane Library were searched fro…

Dengue Fever in Patients with Hematological Malignancies and Hematopoietic Stem Cell Transplantation Recipients: Clinical Characteristics and Outcomes.

Dengue is a hyperendemic arboviral infection with a broad clinical spectrum, ranging from self-limited illness to severe disease with shock and multiorgan dysfunction. Immunosuppressed individuals, particularly patients with hematological malignancies (HM) and those who have undergone hematopoietic cell transplantation (HCT), may be at increased risk for severe manifestations. However, data regarding dengue infection in this population remain limited, especially in endemic settings. Methods: We conducted a retrospective, single-center observational study including adult patients with HM who we…

Long-term outcomes of autologous haematopoietic stem cell transplantation in multiple sclerosis: A retrospective single-centre experience.

BACKGROUND: Autologous haematopoietic stem cell transplantation (AHSCT) is a potential therapeutic strategy for patients with relapsing multiple sclerosis (pwRMS) unresponsive to disease-modifying therapies (DMTs), though its optimal position in the treatment algorithm remains undefined. OBJECTIVE: To describe treatment outcomes of 30 AHSCT performed in 29 pwRMS. METHODS: Retrospective single-centre real-world study. Patients underwent AHSCT between 2001 and 2025. Median age at disease onset, diagnosis, and AHSCT was 21, 23, and 32 years, respectively. Mean EDSS at AHSCT was 3.1 (range 1.0-9…

Sex-associated differences in outcome of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.

[Image: see text]

Artificial intelligence-based predictive model for relapse in acute myeloid leukemia patients following haploidentical hematopoietic cell transplantation.

BACKGROUND AND OBJECTIVES: Relapse is one of the most critical causes of transplant failure in patients with acute myeloid leukemia (AML) receiving haploidentical-related donor (HID) hematopoietic stem cell transplantation (HSCT). We aimed to develop an artificial intelligence (AI)-based predictive model for post-transplant relapse in patients with AML receiving HID HSCT. METHODS: This study included patients with consecutive AML (aged ≥ 12 years) receiving HID HSCT in complete remission (CR). We randomly selected 70% of the entire population (n = 665) as the training cohort for developing th…

Pharmacokinetic variability of vancomycin in patients undergoing hematopoietic stem cell transplantation: a retrospective cohort study in Peru.

BACKGROUND: Vancomycin exhibits high pharmacokinetic variability, particularly in hematopoietic stem cell transplantation (HSCT) patients, where augmented renal clearance (ARC) may compromise therapeutic exposure. This variability necessitates individualized dosing strategies to ensure optimal treatment efficacy. OBJECTIVE: To evaluate the pharmacokinetic variability of vancomycin in pediatric and adult patients undergoing HSCT and to assess the association of ARC with serum drug concentrations. DESIGN: A retrospective cohort study. METHODS: We analyzed medical records of post-HSCT patients…

[Allogeneic hematopoietic stem cell transplantation for pediatric acute leukemia harboring the PICALM-MLLT10 fusion in two cases].

A retrospective analysis was conducted on the clinical course of two children with PICALM-MLLT10-positive acute leukemia treated at Tongji H … llowing conversion to molecular negativity, they underwent sequential allogeneic hematopoietic stem cell transplantation. At the latest follow-up, both patients were alive and in good clinical condition. These observations suggest that proceeding to hematopoietic stem cell transplantation after venetoclax-based chemotherapy may improve the long-term survival of childr …

Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.

Donor age is an important factor influencing outcomes after allogeneic haematopoietic stem cell transplantation (allo-HSCT), but its relevance across donor types and distinct disease biology in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) remains unclear. We analysed 320 patients with AML/MDS who underwent first allo-HSCT between 2016 and 2024. Donors were categorized as matched or mismatched and further stratified as young (<35 years) or old (≥35 years). Matched donors achieved superior survival compared with mismatched donors, while outcomes with young mismatched donors w…

Comprehensive up-to-date analysis on TCRαβ/CD19-depleted hematopoietic stem cell transplantation in pediatric hematological malignancies.

This meta-analysis assesses the efficacy of TCRαβ+/CD19+ depleted hematopoietic stem cell transplantation (HSCT) in pediatric patients with hematological malignancies, bridging the gap in the heterogeneous results of published studies. We analyzed post-HSCT complications and survival outcomes in 1068 children across 14 studies, using both aggregated and patient-level data from acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) and acute lymphoblastic leukemia (ALL) studies, employing the IPDfromKM technique for time-to-event data reconstruction. The analysis reveals a 95 % engraftment …

Trial of Enasidenib Maintenance Post-Allogeneic Hematopoietic Cell Transplantation in Patients with IDH2-Mutated Acute Myeloid Leukemia.

The relapse rate at 1 year is approximately 30% in acute myeloid leukemia (AML) patients with an IDH2 mutation who undergo allogeneic hematopoietic cell transplantation (alloHCT). We designed a 2-center, open-label, single-arm pilot trial to investigate the safety and tolerability of enasidenib as post-HCT maintenance in AML patients carrying the IDH2 mutation (Clinical Trials.gov NCT03728335). Recipients of first alloHCT who had AML with an IDH2 mutation at the time of diagnosis were eligible for maintenance if in complete remission (CR) at day +30 post-HCT, had an Eastern Cooperative Oncolog…

Clinical Characteristics and Prognostic Factors Affecting Clinical Outcomes in Cytomegalovirus Retinitis Following Allogeneic Hematopoietic Stem Cell Transplantation.

Background/Objectives: This study aimed to evaluate the clinical characteristics and identify the prognostic factors affecting visual outcomes, retinal detachment, and recurrence in cytomegalovirus retinitis (CMVR) patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: A retrospective analysis of 54 CMVR patients (84 eyes) who underwent allo-HSCT between 2015 and 2024 was conducted. Ophthalmologic and systemic evaluations were performed. The visual outcomes were classified as improvement, stabilization, and deterioration. Logistic regression and LASSO regre…

Airway epithelial cell chimerism and chronic lung allograft dysfunction associated with ischemia-reperfusion-injury in lung transplantation.

PURPOSE OF REVIEW: The ischemia-reperfusion injury (IRI) of the bronchial epithelium after lung transplant (LTx) leads to tissue-specific stem cells (TSC) activation, promoting their migration and facilitation of airway remodeling characterized by a chimeric mixture of donor-derived and recipient-derived epithelial cells. This process results in airway epithelial cell chimerism, which we will discuss in this review as having a role in the pathogenesis of chronic lung allograft dysfunction (CLAD) in LTx recipients (LTRs). RECENT FINDINGS: In LTx, IRI of the airway epithelium can be significant

Causes and therapeutic limitations of clinical alopecia and the advent of human pluripotent stem cell follicular transplantation.

Hair loss is a prevalent condition that affects many people worldwide and is often associated with self-neglect and anxiety. Hair transplantation is emerging as a viable therapeutic option for addressing several forms of hair loss that are resistant to pharmacological treatments. The etiology of hair loss is multifactorial and includes genetic predisposition, psychological factors, exposure to toxic agents, nutritional deficiencies, and mechanical stress. However, existing treatments, including topical medications, oral therapies, and phototherapy, often fail to provide comprehensive solutions

Allogeneic Hematopoietic Stem Cell Transplantation as a Platform to Treat Chemorefractory Acute Myeloid Leukemia in Adult Patients.

Adult patients affected by acute myeloid leukemia who fail to achieve remission after two cycles of intensive chemotherapy based on a combination of anthracyclines and cytarabine are considered chemorefractory and are unlikely to benefit from further induction attempts. Characterized by a poor prognosis, they may still benefit from allogeneic hematopoietic stem cell transplantation, even if long-term survival rarely exceeds 20-30%. Still, the use of sequential high-dose chemotherapy followed by reduced-intensity conditioning, with transplantation performed during aplasia, and the optimization …